APEX (Assessment of Proteasome inhibition for Extending remissions) trial: phase III randomized, multicenter, placebo-controlled trial to evaluate the efficacy and safety of bortezomib versus dexamethasone in patients with recurrent or treatment-resistant multiple myeloma.
D001897:Boronic Acids / Q000627:therapeutic use* / Q000633:toxicity; D000069286:Bortezomib; D002985:Clinical Protocols; D003907:Dexamethasone / Q000627:therapeutic use* / Q000633:toxicity; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy*; D018579:Patient Selection; D011480:Protease Inhibitors / Q000627:therapeutic use* / Q000633:toxicity; D011719:Pyrazines / Q000627:therapeutic use* / Q000633:toxicity; D012008:Recurrence; D016879:Salvage Therapy / Q000379:methods*
D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone